Navigation Links
NIH, DOD grants to fund prostate cancer, diabetes research at UH
Date:6/27/2012

HOUSTON, June 26, 2012 Researchers at the University of Houston (UH) have been awarded more than $862,000 in federal grants to pursue projects related to prostate cancer, diabetes and obesity. The U.S. Department of Defense (DOD) and National Institutes of Health (NIH) will fund two new prostate cancer projects, while a third NIH grant will support diabetes and obesity research in the UH Center for Nuclear Receptors and Cell Signaling (CNRCS). The center's research projects now account for eight active NIH grants, a key indicator in Tier One rankings.

"Success in today's competitive federal funding landscape is validation of the motivation and ingenuity of our researchers," said Dr. Jan-ke Gustafsson, director of CNRCS. "With these new awards we are now able to explore new avenues of investigation into the treatment and prevention of these important diseases."

The DOD awarded a grant of more than $337,000 this month to fund assistant professor Daniel Frigo's project, "CaMKK beta-AMPK Signaling Axis as a Biomarker and Therapeutic Target for Advanced Prostate Cancer." Prostate cancer, the second most common cancer in American men, is a major research focus of the Frigo laboratory. The award will further the team's work with CaMKK beta-AMPK, a signaling pathway that may be an effective target for treating prostate cancer. The project is scheduled to begin by the end of June.

"Grants are critical to our research, not only for funding but also building and maintaining a reputable track record on the national level," said Frigo. "Our team is eager to begin these new projects as we focus on identifying drug targets for possible clinical trials in the next phases of research."

Last month, Frigo additionally was awarded a $150,000 grant from the NIH's National Cancer Institute to expand his established research involving the treatment and prevention of prostate cancer. The project, "Modulation of Branched-Chain Fatty Acids for the Prevention of Prostate Cancer," will examine how the convergence of specific biological cues and our diets may function to promote cancer and could provide guidance for preventing the disease. The project is Frigo's third to be funded by the NIH, since joining the center in 2010.

Gustafsson also was notified recently of another NIH grant that will support expanded uses for the center's state-of-the-art zebrafish laboratory. The National Institute of Environmental Health Sciences awarded his team more than $375,000 to collaborate with UH computer science professor Ioannis Kakadiaris on diabetes and obesity research. The project is expected to be led by Maria Bondesson, a research assistant professor with the center. The project, "Detection of Obesogens and Diabetogens by Zebrafish Screening Models," will entail screening the effects of chemical compounds that may disrupt the development of the endocrine system. It is widely hypothesized that exposure to certain chemical compounds in developed countries may be responsible for the steady increase in obesity and diabetes in the U.S.

In total, the CNRCS has 27 active grants. Overall, the center's active projects account for more than $18 million in research funding at UH, another significant metric for Tier One status. Established in 2009, CNRCS is a focal point of the UH health initiative. The center's investigators are involved in many aspects of nuclear receptor research and focused on understanding the roles of these receptors in health and disease. Cell signaling is part of a complex system of communication where cells signal each other to decide when to generate new cells. Errors in this processing are responsible for the diseases they study.


'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert  

Related medicine news :

1. Washingtons Life Sciences Discovery Fund awards commercialization grants
2. 2 Grand Challenges Explorations grants for global health
3. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
4. New drug prevents spread of human prostate cancer cells
5. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
6. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
7. Study examines adverse effects among different radiation therapies for prostate cancer
8. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
9. Warren Buffett Has Early Stage Prostate Cancer
10. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
11. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH, DOD grants to fund prostate cancer, diabetes research at UH
(Date:4/29/2016)... ... , ... In an article published April 16th on the New ... lip injections, which she underwent in order to feel more at home at this ... The article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons say ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Awakening , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress ... Onnit brain and mood optimization products to the store is just one more ...
(Date:4/29/2016)... Palm Springs, California (PRWEB) , ... April 29, ... ... It lies at the heart of our nation’s productivity, stability, even security. Most ... profitability for their organizations. , Then why are American workers so unhappy? , ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) ... with sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, ... Run and Walk and 1-mile walk were held to increase awareness about Lyme ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Spine Team ... pain, is proud to announce one of their physicians has been invited to be ... Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
Breaking Medicine Technology: